Back

Age differences in cardiac remodeling, biomarkers and quality-of-life with sacubitril/valsartan in heart failure with reduced ejection fraction

21 May 2022 (08:30 - 18:50)
Organised by:
Congress Presentation Part of: Heart Failure ePosters - focus on Chronic Heart Failure 3 Pharmacotherapy HFA Premium Access Heart Failure 2022

About the speaker

Photo
Doctor Sean Murphy

Sanger Heart and Vascular Institute, Charlotte (United States of America)

35 More presentations in this session

Presentation thumbnail
Dulaglutide and cardiovascular and heart failure outcomes in patients with and without heart failure: A post-hoc analysis from the REWIND randomized trial
Professor K. Branch (Seattle, US)
Abstract Slides
Presentation thumbnail
Prognostic value of pulse pressure in heart failure with preserved ejection fraction: findings from the RICA registry
Doctor I. Bravo Candela (Sevilla, ES)
Abstract Slides
Presentation thumbnail
Repetitive ambulatory doses of levosimendan for patients as bridge to heart transplant. Findings from the LEVO-T registry.
Doctor J. De Juan Baguda (Madrid, ES)
Abstract Slides
Presentation thumbnail
Sacubitril/valsartan use patterns among older adults with heart failure in routine care: a US population-based cohort study of >25,000 medicare beneficiaries
Doctor A. Bhatt (Boston, US)
Abstract Slides
Presentation thumbnail
Efficacy of sodium glucose cotransporter-2 inhibitors for heart failure with preserved and with mildly reduced ejection fraction: a systematic review and meta-analysis
Doctor R. Cordovez (Cebu City, PH)
Abstract Slides

Access the full session

Session thumbnail
Heart Failure ePosters - focus on Chronic Heart Failure 3

The Event

Event poster

Heart Failure 2022

21 May 2022 08:30 CET

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources